NCT02019394View on ClinicalTrials.gov

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2014

Conditions
Healthy
Interventions
DRUG

Lu AE58054

"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."

Trial Locations (1)

NG11 6JS

GB803, Nottingham

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02019394 - Absolute Bioavailability of Lu AE58054 in Healthy Subjects | Biotech Hunter | Biotech Hunter